Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients.
Identifieur interne : 000323 ( Main/Corpus ); précédent : 000322; suivant : 000324Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients.
Auteurs : Markus Bickel ; Imke Wieters ; Pavel Khaykin ; Gabi Nisius ; Annette Haberl ; Christoph Stephan ; Nils Von Hentig ; Eva Herrmann ; Hans W. Doerr ; Hans R. Brodt ; Regina AllwinnSource :
- AIDS (London, England) [ 1473-5571 ] ; 2010.
English descriptors
- KwdEn :
- Age Factors, Antibodies, Viral (blood), CD4 Lymphocyte Count, Female, Germany (epidemiology), HIV-1, Humans, Influenza A Virus, H1N1 Subtype (immunology), Influenza Vaccines (administration & dosage), Influenza Vaccines (immunology), Influenza, Human (epidemiology), Influenza, Human (prevention & control), Male, Middle Aged, Virion (immunology).
- MESH :
- chemical , administration & dosage : Influenza Vaccines.
- chemical , blood : Antibodies, Viral.
- geographic , epidemiology : Germany.
- epidemiology : Influenza, Human.
- immunology : Influenza A Virus, H1N1 Subtype, Influenza Vaccines, Virion.
- prevention & control : Influenza, Human.
- Age Factors, CD4 Lymphocyte Count, Female, HIV-1, Humans, Male, Middle Aged.
Abstract
To determine rates of seroconversion after single vaccination with a novel split virion, inactivated, adjuvanted pandemic H1N1 influenza vaccine (A/California/7/2009) in HIV-1-infected patients (ClinicalTrials.gov Identifier: NCT01017172).
DOI: 10.1097/QAD.0b013e3283398da1
PubMed: 20559034
Links to Exploration step
pubmed:20559034Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients.</title><author><name sortKey="Bickel, Markus" sort="Bickel, Markus" uniqKey="Bickel M" first="Markus" last="Bickel">Markus Bickel</name><affiliation><nlm:affiliation>HIVCENTER, Frankfurt, Germany. markus.bickel@hivcenter.de </nlm:affiliation> </affiliation></author><author><name sortKey="Wieters, Imke" sort="Wieters, Imke" uniqKey="Wieters I" first="Imke" last="Wieters">Imke Wieters</name></author><author><name sortKey="Khaykin, Pavel" sort="Khaykin, Pavel" uniqKey="Khaykin P" first="Pavel" last="Khaykin">Pavel Khaykin</name></author><author><name sortKey="Nisius, Gabi" sort="Nisius, Gabi" uniqKey="Nisius G" first="Gabi" last="Nisius">Gabi Nisius</name></author><author><name sortKey="Haberl, Annette" sort="Haberl, Annette" uniqKey="Haberl A" first="Annette" last="Haberl">Annette Haberl</name></author><author><name sortKey="Stephan, Christoph" sort="Stephan, Christoph" uniqKey="Stephan C" first="Christoph" last="Stephan">Christoph Stephan</name></author><author><name sortKey="Von Hentig, Nils" sort="Von Hentig, Nils" uniqKey="Von Hentig N" first="Nils" last="Von Hentig">Nils Von Hentig</name></author><author><name sortKey="Herrmann, Eva" sort="Herrmann, Eva" uniqKey="Herrmann E" first="Eva" last="Herrmann">Eva Herrmann</name></author><author><name sortKey="Doerr, Hans W" sort="Doerr, Hans W" uniqKey="Doerr H" first="Hans W" last="Doerr">Hans W. Doerr</name></author><author><name sortKey="Brodt, Hans R" sort="Brodt, Hans R" uniqKey="Brodt H" first="Hans R" last="Brodt">Hans R. Brodt</name></author><author><name sortKey="Allwinn, Regina" sort="Allwinn, Regina" uniqKey="Allwinn R" first="Regina" last="Allwinn">Regina Allwinn</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2010">2010</date><idno type="RBID">pubmed:20559034</idno><idno type="pmid">20559034</idno><idno type="doi">10.1097/QAD.0b013e3283398da1</idno><idno type="wicri:Area/Main/Corpus">000323</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000323</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients.</title><author><name sortKey="Bickel, Markus" sort="Bickel, Markus" uniqKey="Bickel M" first="Markus" last="Bickel">Markus Bickel</name><affiliation><nlm:affiliation>HIVCENTER, Frankfurt, Germany. markus.bickel@hivcenter.de </nlm:affiliation> </affiliation></author><author><name sortKey="Wieters, Imke" sort="Wieters, Imke" uniqKey="Wieters I" first="Imke" last="Wieters">Imke Wieters</name></author><author><name sortKey="Khaykin, Pavel" sort="Khaykin, Pavel" uniqKey="Khaykin P" first="Pavel" last="Khaykin">Pavel Khaykin</name></author><author><name sortKey="Nisius, Gabi" sort="Nisius, Gabi" uniqKey="Nisius G" first="Gabi" last="Nisius">Gabi Nisius</name></author><author><name sortKey="Haberl, Annette" sort="Haberl, Annette" uniqKey="Haberl A" first="Annette" last="Haberl">Annette Haberl</name></author><author><name sortKey="Stephan, Christoph" sort="Stephan, Christoph" uniqKey="Stephan C" first="Christoph" last="Stephan">Christoph Stephan</name></author><author><name sortKey="Von Hentig, Nils" sort="Von Hentig, Nils" uniqKey="Von Hentig N" first="Nils" last="Von Hentig">Nils Von Hentig</name></author><author><name sortKey="Herrmann, Eva" sort="Herrmann, Eva" uniqKey="Herrmann E" first="Eva" last="Herrmann">Eva Herrmann</name></author><author><name sortKey="Doerr, Hans W" sort="Doerr, Hans W" uniqKey="Doerr H" first="Hans W" last="Doerr">Hans W. Doerr</name></author><author><name sortKey="Brodt, Hans R" sort="Brodt, Hans R" uniqKey="Brodt H" first="Hans R" last="Brodt">Hans R. Brodt</name></author><author><name sortKey="Allwinn, Regina" sort="Allwinn, Regina" uniqKey="Allwinn R" first="Regina" last="Allwinn">Regina Allwinn</name></author></analytic><series><title level="j">AIDS (London, England)</title><idno type="eISSN">1473-5571</idno><imprint><date when="2010" type="published">2010</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Age Factors</term><term>Antibodies, Viral (blood)</term><term>CD4 Lymphocyte Count</term><term>Female</term><term>Germany (epidemiology)</term><term>HIV-1</term><term>Humans</term><term>Influenza A Virus, H1N1 Subtype (immunology)</term><term>Influenza Vaccines (administration & dosage)</term><term>Influenza Vaccines (immunology)</term><term>Influenza, Human (epidemiology)</term><term>Influenza, Human (prevention & control)</term><term>Male</term><term>Middle Aged</term><term>Virion (immunology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Germany</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term><term>Influenza Vaccines</term><term>Virion</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Age Factors</term><term>CD4 Lymphocyte Count</term><term>Female</term><term>HIV-1</term><term>Humans</term><term>Male</term><term>Middle Aged</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To determine rates of seroconversion after single vaccination with a novel split virion, inactivated, adjuvanted pandemic H1N1 influenza vaccine (A/California/7/2009) in HIV-1-infected patients (ClinicalTrials.gov Identifier: NCT01017172).</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20559034</PMID><DateCompleted><Year>2010</Year><Month>12</Month><Day>30</Day></DateCompleted><DateRevised><Year>2010</Year><Month>06</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1473-5571</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>9</Issue><PubDate><Year>2010</Year><Month>Jun</Month><Day>01</Day></PubDate></JournalIssue><Title>AIDS (London, England)</Title><ISOAbbreviation>AIDS</ISOAbbreviation></Journal><ArticleTitle>Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients.</ArticleTitle><Pagination><MedlinePgn>F31-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/QAD.0b013e3283398da1</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine rates of seroconversion after single vaccination with a novel split virion, inactivated, adjuvanted pandemic H1N1 influenza vaccine (A/California/7/2009) in HIV-1-infected patients (ClinicalTrials.gov Identifier: NCT01017172).</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Single center diagnostic study.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Institutional HIV outpatient department of an urban university clinic.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">Adult HIV-1-infected individuals.</AbstractText><AbstractText Label="INTERVENTION" NlmCategory="METHODS">Serum samples were taken before and 21 days after vaccination.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Antibody titers determined by hemagglutination inhibition assay. Seroconversion to vaccination was defined by either an antibody titer of 1: 10 or less before and of at least 1: 40 after or at least 1: 10 before and at least four-fold increase in antibody titer 21 days after single vaccination.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">One hundred and sixty patients (125 men/35 women) were analyzed. Before vaccination, 23 patients (14.4%) had a hemagglutination inhibition assay titer of at least 1: 40. A median of 22 +/- 3 days after vaccination, 110 (69%) patients seroconverted. Seroconverters were younger (45.1 +/- 10.0 vs. 48.8 +/- 11.3 years; P = 0.04), had a higher CD4 cell count (532 +/- 227 vs. 475 +/- 281 cells/microl; P = 0.03) and were more likely to have received a previous H5N1 vaccination in 2009 (25 vs. 8%; P = 0.02) when compared to nonresponders. No other significant differences were found comparing the two groups (prevaccination hemagglutination inhibition assay titer of > or =1: 40, AIDS, HAART, HIV RNA PCR <50 copies/ml or CD4 nadir, CD4 and CD8 percentage, sex, BMI, chronic hepatitis B or C).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Seroconversion after one dose of a split virion, inactivated, adjuvanted pandemic H1N1 influenza vaccine of HIV-infected patients was 69%. Studies to investigate whether a second dose of the vaccine will increase seroconversion rate are needed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bickel</LastName><ForeName>Markus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>HIVCENTER, Frankfurt, Germany. markus.bickel@hivcenter.de </Affiliation> </AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wieters</LastName><ForeName>Imke</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Khaykin</LastName><ForeName>Pavel</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Nisius</LastName><ForeName>Gabi</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Haberl</LastName><ForeName>Annette</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Stephan</LastName><ForeName>Christoph</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Von Hentig</LastName><ForeName>Nils</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Herrmann</LastName><ForeName>Eva</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Doerr</LastName><ForeName>Hans W</ForeName><Initials>HW</Initials></Author><Author ValidYN="Y"><LastName>Brodt</LastName><ForeName>Hans R</ForeName><Initials>HR</Initials></Author><Author ValidYN="Y"><LastName>Allwinn</LastName><ForeName>Regina</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01017172</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>AIDS</MedlineTA><NlmUniqueID>8710219</NlmUniqueID><ISSNLinking>0269-9370</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CitationSubset>X</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>AIDS. 2010 Aug 24;24(13):2142-3</RefSource><PMID Version="1">20679764</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018791" MajorTopicYN="N">CD4 Lymphocyte Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015497" MajorTopicYN="Y">HIV-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014771" MajorTopicYN="N">Virion</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>6</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>6</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>12</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20559034</ArticleId><ArticleId IdType="doi">10.1097/QAD.0b013e3283398da1</ArticleId><ArticleId IdType="pii">00002030-201006010-00001</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=ExplorPubmed/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000323 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000323 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= ExplorPubmed
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:20559034
|texte= Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:20559034" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ExplorPubmed
| This area was generated with Dilib version V0.6.35. |  |